EBGLYSS Durable Efficacy: Lilly Reports Landmark 4-Year Results for Atopic Dermatitis

Quick Summary

Exceptional Long-Term Efficacy: After four years of continuous treatment, 94% of patients achieved significant skin improvement (EASI-75), and 75% reached near-complete skin clearance (EASI-90). Additionally, 78% experienced meaningful relief from chronic itch.
Steroid-Free Disease Control: The results were achieved with high independence from other treatments; 80% of patients maintained their skin clearance without the need for topical corticosteroids, highlighting the drug’s ability to manage the underlying inflammation.
Convenient Monthly Maintenance: These durable results were sustained using a once-monthly maintenance dosing schedule (250 mg every four weeks), offering a consistent safety profile with no new long-term side effects identified.

EBGLYSS durable efficacy has taken center stage in the dermatology world as Eli Lilly and Company (NYSE: LLY) recently announced groundbreaking four-year data from its clinical program. The results from the ADlong Phase 3b study demonstrate that EBGLYSS (lebrikizumab-lbkz) provides sustained, long-term disease control for patients suffering from moderate-to-severe atopic dermatitis (AD), commonly known as eczema.

For millions of patients worldwide, the chronic nature of atopic dermatitis, characterized by unpredictable flares, intense itching, and visible skin damage, requires a treatment that doesn’t just work in the short term but remains effective over many years. These new findings suggest that EBGLYSS may be the transformative solution the medical community has been seeking.

Breaking Down the ADlong Study: Sustaining EBGLYSS Durable Efficacy

The ADlong study is an open-label extension trial designed to evaluate the long-term safety and efficacy of EBGLYSS. The latest interim results are particularly striking because they show that the vast majority of patients who responded to the initial treatment maintained those benefits for up to 208 weeks (four years).

According to the data presented at the American Academy of Dermatology (AAD) Annual Meeting, the clinical outcomes for patients on continuous EBGLYSS treatment were as follows:

EASI-75 Achievement: An incredible 94% of patients achieved at least a 75% reduction in skin inflammation (measured by the Eczema Area and Severity Index).
Near-Complete Clearance: 75% of participants reached EASI-90, a high bar of skin clearance that signifies nearly clear skin.
Itch Relief: 78% of patients experienced significant relief from itch, one of the most debilitating symptoms of the condition, achieving a Pruritus NRS score of ≤4.
Clear or Almost Clear Skin: 68% of patients maintained an Investigator’s Global Assessment (IGA) score of 0 or 1.

The significance of EBGLYSS durable efficacy is further underscored by the fact that 80% of these patients achieved these results without the need for topical corticosteroids (TCS). This is a critical finding, as long-term use of topical steroids can lead to skin thinning and other side effects.

The Science Behind the Success: Targeting IL-13

EBGLYSS is a monoclonal antibody that targets interleukin-13 (IL-13) with high binding affinity and a slow dissociation rate. IL-13 is widely recognized as a primary driver of the type-2 inflammatory cycle in the skin. By selectively blocking this cytokine, EBGLYSS helps restore the skin barrier, reduce skin thickening, and alleviate the “itch-scratch” cycle that plagues eczema patients.

What sets this therapy apart is not just its targeted mechanism but its convenient dosing schedule. Following an initial induction phase, the maintenance dose is just one 250 mg injection every four weeks. This monthly dosing is a major differentiator compared to other biologics that often require bi-weekly administration, further enhancing the appeal of EBGLYSS durable efficacy in real-world settings.

Expanding Reach: From Adults to Infants

While the four-year data primarily focused on adults and adolescents (12 years and older), Lilly is also making strides in pediatric care. Recently, the company announced positive topline results from the Phase 3 ADorable-1 trial, which evaluated EBGLYSS in children as young as six months to 18 years.

In that study, 63% of pediatric patients achieved EASI-75 by Week 16. These findings suggest that the benefits of this selective IL-13 inhibitor could soon extend to the youngest and most vulnerable patients, providing a new standard of care across the lifespan.

Safety and Tolerability Over the Long Term

A major concern with long-term biologic use is the potential for late-emerging side effects. However, the four-year data for EBGLYSS showed a safety profile consistent with previous two- and three-year reports. The most common adverse events included:

Eye and eyelid inflammation (conjunctivitis).
Injection site reactions.
Shingles (herpes zoster).

Eli Lilly and Company — Image: Eli Lilly

Study Data

Clinical Endpoint	Definition	Result at 4 Years (Week 208)
EASI-75	≥75% improvement in skin clearance	94%
EASI-90	≥90% improvement (Near-complete clearance)	75%
IGA 0 or 1	Skin is “Clear” or “Almost Clear”	68%
Itch Relief (NRS $\le 4$)	Significant reduction in itch intensity	78%
Corticosteroid-Free	Achieving EASI-75 without topical steroid use	80%

Key Takeaways from the Data

Sustained Response: The most notable aspect of this data is the stability of the response. The high percentages at Year 4 are consistent with Year 2 and Year 3 results, proving that EBGLYSS durable efficacy does not diminish significantly over time.
Convenient Dosing: These results were achieved with a once-monthly (Q4W) maintenance regimen, offering a lower treatment burden compared to many bi-weekly biologics.
Safety Profile: No new safety signals were identified over the four-year period. The most common side effects remained mild to moderate, primarily consisting of conjunctivitis and injection site reactions.

Eli Lilly and Company

Clinical Trials & Data Desk

+ posts